NLS Pharmaceutics Amends Merger Agreement for Seventh Time
Ticker: NCEL · Form: 6-K · Filed: Aug 29, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Aug 29, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: merger-agreement, amendment, legal
TL;DR
NLS Pharma just signed its SEVENTH amendment to a merger deal. Still cooking.
AI Summary
On August 29, 2025, NLS Pharmaceutics Ltd. entered into the Seventh Amendment to its Merger Agreement, originally dated November 4, 2024. This marks the seventh amendment to the agreement, following previous modifications on January 30, February 17, May 5, June 5, July 1, and July 18, 2025.
Why It Matters
This filing indicates ongoing adjustments to a significant merger agreement, suggesting potential complexities or evolving terms in the transaction.
Risk Assessment
Risk Level: medium — Frequent amendments to a merger agreement can signal underlying issues or complexities in the deal's execution.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — The company filing the report and entering into the amendment.
- August 29, 2025 (date) — Date the Seventh Amendment was entered into.
- November 4, 2024 (date) — Original date of the Agreement and Plan of Merger.
FAQ
What is the primary purpose of the Seventh Amendment to the Merger Agreement?
The filing does not specify the purpose of the Seventh Amendment, only that NLS Pharmaceutics Ltd. entered into it on August 29, 2025.
When was the original Merger Agreement signed?
The original Agreement and Plan of Merger was dated November 4, 2024.
How many times has the Merger Agreement been amended prior to this filing?
The Merger Agreement had been amended six times prior to the Seventh Amendment, on January 30, February 17, May 5, June 5, July 1, and July 18, 2025.
What is the filing number for NLS Pharmaceutics Ltd.'s SEC filings?
The SEC file number for NLS Pharmaceutics Ltd. is 001-39957.
Where is NLS Pharmaceutics Ltd. headquartered?
NLS Pharmaceutics Ltd. is headquartered in Zurich, Switzerland.
Filing Stats: 1,184 words · 5 min read · ~4 pages · Grade level 15.1 · Accepted 2025-08-29 16:01:10
Filing Documents
- ea0254962-6k_nlspharma.htm (6-K) — 20KB
- ea025496201ex99-1_nlspharma.htm (EX-99.1) — 13KB
- 0001213900-25-082550.txt ( ) — 34KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: August 29, 2025 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 3